Medical - Instruments & Supplies
Compare Stocks
4 / 10Stock Comparison
KRMD vs INFU vs AVNS vs BDX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Devices
Medical - Instruments & Supplies
KRMD vs INFU vs AVNS vs BDX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $207M | $181M | $1.16B | $55.53B |
| Revenue (TTM) | $43M | $142M | $716M | $21.36B |
| Net Income (TTM) | $-2M | $8M | $-69M | $1.14B |
| Gross Margin | 60.1% | 56.7% | 49.4% | 46.5% |
| Operating Margin | -5.1% | 9.1% | -8.4% | 10.6% |
| Forward P/E | — | 21.5x | 24.8x | 12.3x |
| Total Debt | $3M | $3M | $129M | $19.18B |
| Cash & Equiv. | $9M | $3M | $90M | $851M |
KRMD vs INFU vs AVNS vs BDX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| KORU Medical System… (KRMD) | 100 | 43.9 | -56.1% |
| InfuSystem Holdings… (INFU) | 100 | 77.2 | -22.8% |
| Avanos Medical, Inc. (AVNS) | 100 | 85.2 | -14.8% |
| Becton, Dickinson a… (BDX) | 100 | 103.0 | +3.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KRMD vs INFU vs AVNS vs BDX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
KRMD is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 22.2%, EPS growth 56.1%, 3Y rev CAGR 13.8%
- 11.2% 10Y total return vs BDX's 80.2%
- Lower volatility, beta 1.15, Low D/E 20.5%, current ratio 2.44x
- Beta 1.15, current ratio 2.44x
INFU is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 5.6% margin vs AVNS's -9.7%
- 7.9% ROA vs KRMD's -8.3%, ROIC 12.5% vs -19.5%
AVNS is the clearest fit if your priority is momentum.
- +96.9% vs BDX's +51.8%
BDX carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 1 yrs, beta 0.66, yield 2.7%
- Lower P/E (12.3x vs 24.8x)
- Beta 0.66 vs AVNS's 1.54
- 2.7% yield; 1-year raise streak; the other 3 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 22.2% revenue growth vs AVNS's 1.9% | |
| Value | Lower P/E (12.3x vs 24.8x) | |
| Quality / Margins | 5.6% margin vs AVNS's -9.7% | |
| Stability / Safety | Beta 0.66 vs AVNS's 1.54 | |
| Dividends | 2.7% yield; 1-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +96.9% vs BDX's +51.8% | |
| Efficiency (ROA) | 7.9% ROA vs KRMD's -8.3%, ROIC 12.5% vs -19.5% |
KRMD vs INFU vs AVNS vs BDX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
KRMD vs INFU vs AVNS vs BDX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INFU leads in 3 of 6 categories
KRMD leads 1 • AVNS leads 0 • BDX leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
INFU leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BDX is the larger business by revenue, generating $21.4B annually — 493.9x KRMD's $43M. INFU is the more profitable business, keeping 5.6% of every revenue dollar as net income compared to AVNS's -9.7%. On growth, KRMD holds the edge at +22.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $43M | $142M | $716M | $21.4B |
| EBITDAEarnings before interest/tax | -$1M | $23M | -$21M | $4.2B |
| Net IncomeAfter-tax profit | -$2M | $8M | -$69M | $1.1B |
| Free Cash FlowCash after capex | $179,290 | $22M | $24M | $3.1B |
| Gross MarginGross profit ÷ Revenue | +60.1% | +56.7% | +49.4% | +46.5% |
| Operating MarginEBIT ÷ Revenue | -5.1% | +9.1% | -8.4% | +10.6% |
| Net MarginNet income ÷ Revenue | -5.3% | +5.6% | -9.7% | +5.3% |
| FCF MarginFCF ÷ Revenue | +0.4% | +15.4% | +3.4% | +14.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.1% | -3.0% | +8.8% | -10.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +33.3% | +6.0% | -21.4% | -2.0% |
Valuation Metrics
INFU leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 26.3x trailing earnings, BDX trades at a 9% valuation discount to INFU's 28.9x P/E. On an enterprise value basis, INFU's 7.2x EV/EBITDA is more attractive than BDX's 14.7x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $207M | $181M | $1.2B | $55.5B |
| Enterprise ValueMkt cap + debt − cash | $201M | $181M | $1.2B | $73.9B |
| Trailing P/EPrice ÷ TTM EPS | -77.76x | 28.90x | -16.97x | 26.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 21.54x | 24.77x | 12.27x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 1.59x |
| EV / EBITDAEnterprise value multiple | — | 7.19x | — | 14.65x |
| Price / SalesMarket cap ÷ Revenue | 5.02x | 1.26x | 1.65x | 2.54x |
| Price / BookPrice ÷ Book value/share | 12.03x | 3.30x | 1.48x | 1.73x |
| Price / FCFMarket cap ÷ FCF | — | 7.59x | 26.91x | 20.80x |
Profitability & Efficiency
INFU leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
INFU delivers a 14.0% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-14 for KRMD. INFU carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to BDX's 0.76x. On the Piotroski fundamental quality scale (0–9), INFU scores 8/9 vs AVNS's 5/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -13.6% | +14.0% | -8.9% | +4.5% |
| ROA (TTM)Return on assets | -8.3% | +7.9% | -6.6% | +2.1% |
| ROICReturn on invested capital | -19.5% | +12.5% | -5.4% | +4.3% |
| ROCEReturn on capital employed | -14.9% | +14.3% | -6.5% | +5.4% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 8 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.21x | 0.06x | 0.17x | 0.76x |
| Net DebtTotal debt minus cash | -$5M | $241,000 | $39M | $18.3B |
| Cash & Equiv.Liquid assets | $9M | $3M | $90M | $851M |
| Total DebtShort + long-term debt | $3M | $3M | $129M | $19.2B |
| Interest CoverageEBIT ÷ Interest expense | — | 13.65x | -16.71x | 4.09x |
Total Returns (Dividends Reinvested)
KRMD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KRMD five years ago would be worth $12,402 today (with dividends reinvested), compared to $4,297 for INFU. Over the past 12 months, AVNS leads with a +96.9% total return vs BDX's +51.8%. The 3-year compound annual growth rate (CAGR) favors KRMD at 4.2% vs INFU's 0.9% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -20.9% | +6.8% | +121.6% | +0.7% |
| 1-Year ReturnPast 12 months | +63.2% | +88.6% | +96.9% | +51.8% |
| 3-Year ReturnCumulative with dividends | +13.3% | +2.8% | +5.6% | +5.0% |
| 5-Year ReturnCumulative with dividends | +24.0% | -57.0% | -39.8% | +16.9% |
| 10-Year ReturnCumulative with dividends | +1116.4% | +159.0% | -17.0% | +80.2% |
| CAGR (3Y)Annualised 3-year return | +4.2% | +0.9% | +1.8% | +1.6% |
Risk & Volatility
Evenly matched — AVNS and BDX each lead in 1 of 2 comparable metrics.
Risk & Volatility
BDX is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than AVNS's 1.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AVNS currently trades 99.9% from its 52-week high vs KRMD's 67.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.15x | 1.50x | 1.54x | 0.66x |
| 52-Week HighHighest price in past year | $6.61 | $11.04 | $24.80 | $205.52 |
| 52-Week LowLowest price in past year | $2.63 | $4.70 | $9.30 | $100.31 |
| % of 52W HighCurrent price vs 52-week peak | +67.2% | +81.2% | +99.9% | +74.6% |
| RSI (14)Momentum oscillator 0–100 | 42.9 | 51.5 | 90.8 | 32.2 |
| Avg Volume (50D)Average daily shares traded | 138K | 121K | 1.3M | 2.5M |
Analyst Outlook
Evenly matched — AVNS and BDX each lead in 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: KRMD as "Buy", INFU as "Buy", AVNS as "Hold", BDX as "Buy". Consensus price targets imply 67.4% upside for INFU (target: $15) vs -7.1% for AVNS (target: $23). BDX is the only dividend payer here at 2.72% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $7.00 | $15.00 | $23.00 | $172.85 |
| # AnalystsCovering analysts | 5 | 3 | 8 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +2.7% |
| Dividend StreakConsecutive years of raises | 0 | — | 1 | 1 |
| Dividend / ShareAnnual DPS | — | — | — | $4.17 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +6.1% | +0.3% | +1.8% |
INFU leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). KRMD leads in 1 (Total Returns). 2 tied.
KRMD vs INFU vs AVNS vs BDX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is KRMD or INFU or AVNS or BDX a better buy right now?
For growth investors, KORU Medical Systems, Inc.
(KRMD) is the stronger pick with 22. 2% revenue growth year-over-year, versus 1. 9% for Avanos Medical, Inc. (AVNS). Becton, Dickinson and Company (BDX) offers the better valuation at 26. 3x trailing P/E (12. 3x forward), making it the more compelling value choice. Analysts rate KORU Medical Systems, Inc. (KRMD) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — KRMD or INFU or AVNS or BDX?
On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 26.
3x versus InfuSystem Holdings, Inc. at 28. 9x. On forward P/E, Becton, Dickinson and Company is actually cheaper at 12. 3x.
03Which is the better long-term investment — KRMD or INFU or AVNS or BDX?
Over the past 5 years, KORU Medical Systems, Inc.
(KRMD) delivered a total return of +24. 0%, compared to -57. 0% for InfuSystem Holdings, Inc. (INFU). Over 10 years, the gap is even starker: KRMD returned +1116% versus AVNS's -17. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — KRMD or INFU or AVNS or BDX?
By beta (market sensitivity over 5 years), Becton, Dickinson and Company (BDX) is the lower-risk stock at 0.
66β versus Avanos Medical, Inc. 's 1. 54β — meaning AVNS is approximately 135% more volatile than BDX relative to the S&P 500. On balance sheet safety, InfuSystem Holdings, Inc. (INFU) carries a lower debt/equity ratio of 6% versus 76% for Becton, Dickinson and Company — giving it more financial flexibility in a downturn.
05Which is growing faster — KRMD or INFU or AVNS or BDX?
By revenue growth (latest reported year), KORU Medical Systems, Inc.
(KRMD) is pulling ahead at 22. 2% versus 1. 9% for Avanos Medical, Inc. (AVNS). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -0. 5% for Becton, Dickinson and Company. Over a 3-year CAGR, KRMD leads at 13. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — KRMD or INFU or AVNS or BDX?
Becton, Dickinson and Company (BDX) is the more profitable company, earning 7.
7% net margin versus -9. 7% for Avanos Medical, Inc. — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDX leads at 11. 8% versus -8. 8% for AVNS. At the gross margin level — before operating expenses — KRMD leads at 60. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is KRMD or INFU or AVNS or BDX more undervalued right now?
On forward earnings alone, Becton, Dickinson and Company (BDX) trades at 12.
3x forward P/E versus 24. 8x for Avanos Medical, Inc. — 12. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INFU: 67. 4% to $15. 00.
08Which pays a better dividend — KRMD or INFU or AVNS or BDX?
In this comparison, BDX (2.
7% yield) pays a dividend. KRMD, INFU, AVNS do not pay a meaningful dividend and should not be held primarily for income.
09Is KRMD or INFU or AVNS or BDX better for a retirement portfolio?
For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
66), 2. 7% yield). Avanos Medical, Inc. (AVNS) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BDX: +80. 2%, AVNS: -17. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between KRMD and INFU and AVNS and BDX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KRMD is a small-cap high-growth stock; INFU is a small-cap quality compounder stock; AVNS is a small-cap quality compounder stock; BDX is a mid-cap quality compounder stock. BDX pays a dividend while KRMD, INFU, AVNS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.